State Medicaid pharmacy directors and Preferred Drug List (PDL) committees across the country face a pivotal deadline: September 10, 2026, the final date to submit state applications to participate in the Centers for Medicare & Medicaid Services (CMS) GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model, followed by a September 30, 2026 deadline to execute formal participation agreements.
Announced under the Center for Medicare and Medicaid Innovation (CMMI) authority, the GENEROUS model represents the federal government's most direct effort to bring international Most-Favored-Nation (MFN) drug pricing into Medicaid. In exchange for manufacturer supplemental rebates pegged to the second-lowest net price among eight peer nations, participating states must adopt standardized, federally negotiated coverage criteria on selected brand-name outpatient drugs.
While mainstream policy summaries often treat GENEROUS as a straightforward price-discount program, the operational reality for state Medicaid agencies, Medicaid managed care organizations (MCOs), and pharmacy benefit managers (PBMs) is far more complex. GENEROUS is a coverage-criteria consolidation program with a price attached. To secure MFN net pricing, states must surrender their primary source of contracting leverage: the ability to design state-specific prior authorization criteria and negotiate independent supplemental rebates on model drugs.
This analysis examines the exact mechanics of the GENEROUS model, walks through the supplemental rebate arithmetic with CMS's worked example, explores the three-document participation architecture, maps the state winners and losers from peer-reviewed evidence, and provides an operational evaluation framework for state access teams.
What is actually due on September 10 and September 30, 2026?
The operational timeline for the GENEROUS model has evolved through multiple administrative adjustments. While early policy analyses (such as KFF's initial issue brief) reported July 31 and August 31 deadlines, CMS formally extended the schedule in a 2026 news alert to give states and manufacturers adequate time to operationalize the model's complex contracting architecture.
┌────────────────────────────────────────────────────────────────────────┐
│ GENEROUS Model Procedural & Deadline Timeline │
├──────────────────────────────────┬─────────────────────────────────────┤
│ Milestone Date │ Operational Deliverable │
├──────────────────────────────────┼─────────────────────────────────────┤
│ November 2025 │ • Model announced; manufacturer RFA │
│ December 2025 │ • State RFA released │
│ June 11, 2026 (from Apr 30) │ • Manufacturer application deadline │
│ July 17, 2026 (from Jun 30) │ • Manufacturer participation │
│ │ agreement execution deadline │
│ September 10, 2026 (from Jul 31) │ • State Medicaid application │
│ │ deadline │
│ September 30, 2026 (from Aug 31) │ • State participation agreement │
│ │ execution deadline │
│ Performance Period │ • Five performance years, beginning │
│ │ on a rolling basis Jan 1, 2026, │
│ │ ending Dec 31, 2030 │
└──────────────────────────────────┴─────────────────────────────────────┘
Two details in that timeline are easy to misread. The performance period begins January 1, 2026 on a rolling basis — a state that signs in late September 2026 does not lose the earlier months, because participating manufacturers agree to provide MFN rebates "retroactive to January 1, 2026, for states that participate in the model according to the direction to be provided by CMS." A state may then effectuate its SRA at any point after executing its CMS participation agreement and before December 31, 2030. The September 10 date is the gate to the model, not the gate to a particular start date.
All four deadlines above were extended once already, by a CMS news alert dated April 29, 2026. That is context, not a prediction: nothing in the public record indicates a further extension, and a state should plan against September 10.
Statutory Authority and Model Scope
The model operates under Section 1115A of the Social Security Act (42 U.S.C. § 1315a), which authorizes CMMI to test innovative payment and service delivery models to reduce program expenditures while preserving or enhancing quality of care.
The scope of the model is subject to precise statutory and regulatory boundaries:
- Eligible Drug Categories: All single source and innovator multiple source covered outpatient drugs of a participating manufacturer, as described in 42 CFR § 447.502, plus blood clotting factors and drugs approved exclusively for pediatric indications — the two categories that carry the lower 17.1% statutory minimum rebate rather than 23.1%. A "model drug" is defined at the NDC-9 level: active ingredient, dosage form, and strength.
- Voluntary Dual Structure: Participation is completely voluntary for both manufacturers and state Medicaid agencies.
- Drug-by-Drug State Selection: A participating state is not forced to adopt a manufacturer's entire portfolio; states select which specific covered outpatient drugs they wish to access at GENEROUS pricing.
- Twelve-Month Price Guarantee: The model's Most-Favored-Nation price is guaranteed to a participating state for at least 12 consecutive months from the effective date of the supplemental rebate agreement.
This initiative is structurally distinct from other federal pricing initiatives. While the cash-channel discounts we analyzed in the TrumpRx most-favored-nation framework focus on direct-to-consumer pharmacy point-of-sale pricing, GENEROUS operates entirely within the Medicaid Drug Rebate Program (MDRP) infrastructure.
How is the most-favored-nation price calculated and how does the supplemental rebate arithmetic work?
The core economic engine of the GENEROUS model is the Guaranteed Net Unit Price (GNUP), which establishes a federally benchmarked net price ceiling for each model drug.
The 8-Country MFN Benchmark
Under the CMS State Request for Applications (RFA), the MFN benchmark price is calculated at the NDC-9 level (identifying the specific drug substance, dosage form, and strength) using the following methodology:
- Eight Reference Nations: The RFA defines the basket as "G-7 countries other than the United States (the United Kingdom, France, Germany, Italy, Canada, and Japan), plus Denmark and Switzerland," and states the list "will remain stable over the course of the five-year model test period." That stability commitment matters for a state modeling five-year budget impact: the basket cannot be re-cut mid-model to chase a lower benchmark.
- Manufacturer-Reported Net Prices: Participating manufacturers must submit country-specific net prices realized across all eight nations, net of all statutory rebates, confidential commercial discounts, volume concessions, and price clawbacks.
- Second-Lowest Price Rule: CMS identifies the second-lowest country-specific net price among the eight reference nations. CMS does not publish a rationale for choosing second-lowest over lowest; the practical effect is that a single outlier country cannot set the US benchmark by itself.
- Purchasing Power Parity (PPP) Adjustment: The second-lowest price is adjusted by gross domestic product (GDP) per capita on a PPP basis to ensure comparability with the US macroeconomic baseline.
Reference Countries: [UK, France, Germany, Italy, Canada, Japan, Denmark, Switzerland]
│
▼
Manufacturer-Reported Net Prices (Net of all global discounts)
│
▼
Rank Net Prices ──► Select 2nd Lowest Country ──► Adjust for GDP / PPP ──► GNUP
The Supplemental Rebate Formula
In standard Medicaid reimbursement, states collect the statutory federal Unit Rebate Amount (URA) established under Section 1927 of the Social Security Act. Under GENEROUS, the additional discount required to reach the GNUP is delivered to the state in the form of a CMS-authorized supplemental rebate.
The CMS State RFA establishes the exact formula:
Supplemental Rebate per Unit = WAC - (GNUP + URA)
Where:
- WAC = Wholesale Acquisition Cost published by the manufacturer.
- GNUP = Guaranteed Net Unit Price established under the MFN benchmark.
- URA = Statutory Federal Unit Rebate Amount (calculated under basic rebate plus additional CPI inflation penalty formulas).
Worked Example (From CMS State RFA)
To understand how these layers interact, consider CMS's official worked example from the State RFA:
┌────────────────────────────────────────────────────────────────────────┐
│ CMS Worked Example: GENEROUS Supplemental Rebate │
├────────────────────────────────────────┬───────────────────────────────┤
│ Parameter │ Value per Unit (e.g., Tablet) │
├────────────────────────────────────────┼───────────────────────────────┤
│ Wholesale Acquisition Cost (WAC) │ $2.00 │
│ Statutory Unit Rebate Amount (URA) │ $0.25 │
│ Guaranteed Net Unit Price (GNUP / MFN) │ $0.50 │
├────────────────────────────────────────┼───────────────────────────────┤
│ Calculation: │ │
│ Supplemental Rebate = WAC - (GNUP+URA) │ $2.00 - ($0.50 + $0.25) │
│ Supplemental Rebate Amount │ = $1.25 │
├────────────────────────────────────────┼───────────────────────────────┤
│ Total State Rebate Collected: │ │
│ Total Rebate = Statutory URA + Supp │ $0.25 + $1.25 = $1.50 │
│ Final State Net Acquisition Cost │ WAC ($2.00) - Rebates ($1.50) │
│ State Net Cost Realized │ = $0.50 (= GNUP) │
└────────────────────────────────────────┴───────────────────────────────┘
Through this arithmetic, the state's net expenditure per unit after all rebates exactly equals the GNUP ($0.50), fulfilling the MFN price guarantee. For access teams unfamiliar with basic statutory formulas, our foundational guide on how the Medicaid Drug Rebate Program works explains the underlying AMP and URA mechanics.
What coverage-criteria control does a state hand to CMS by joining?
The price discount under GENEROUS is not unconditional. In exchange for the GNUP, a participating state enters into binding coverage commitments that fundamentally reshape its pharmacy utilization management.
┌────────────────────────────────────────────────────────────────────────┐
│ The GENEROUS Trade: What States Gain vs Give Up │
├──────────────────────────────────┬─────────────────────────────────────┤
│ What the State Gains │ What the State Surrenders │
├──────────────────────────────────┼─────────────────────────────────────┤
│ • MFN price ceiling (GNUP) │ • Must adopt uniform CMS-negotiated │
│ • 12-month net price stability │ coverage criteria on model drugs │
│ • Protection against price hikes │ • Prohibited from negotiating any │
│ • No Best Price / 340B penalty │ additional supplemental rebates │
│ • Standardized contract addenda │ • Cannot disfavor model drugs in │
│ for managed care plans (MCOs) │ same class on Preferred Drug List │
└──────────────────────────────────┴─────────────────────────────────────┘
1. Mandatory Adoption of Uniform Coverage Criteria
Under the State RFA, CMS asks each participating manufacturer to propose uniform coverage terms for its covered outpatient drugs. The RFA says these "may include suggested criteria for utilization management, such as step therapy, quantity limits, and other terms for prior authorization," and that manufacturers' proposed criteria "should reflect the current criteria that they have negotiated with the states." Final terms are negotiated between CMS and the manufacturer with state input, then "adopted by the states if they choose to access the MFN pricing of the manufacturer's drugs."
Read that adoption language carefully, because the published documents are less specific than most summaries imply. The RFA establishes that a participating state adopts the negotiated criteria for the drugs it selects. It does not publish the criteria themselves, and it does not spell out how much a state may layer on top in fee-for-service. For managed care it points the other way: CMS provides a contract template for MCOs, prepaid inpatient health plans, and their PBMs, but "states can further tailor these contract addenda if they participate in the model."
What this means for a state evaluating participation: the utilization-management concession is real but its exact perimeter is not yet public, because the negotiated Key Terms are disclosed to a state by CMS or the manufacturer when the state assesses which drugs to select — not in advance in the RFA. A state cannot fully price this trade from public documents before requesting the Key Terms.
2. Prohibition on Additional Supplemental Rebates
Under the CMS State RFA, a participating state is strictly prohibited from negotiating any additional supplemental rebate for a covered outpatient drug on which it accesses GENEROUS pricing. While the state remains free to negotiate supplemental rebates on non-model drugs or across other manufacturers' portfolios, its negotiating authority on model drugs is completely superseded by the federal agreement.
3. The Same-Class Non-Discrimination Constraint
The most significant operational restriction for state PDL design is the same-class non-discrimination rule.
If a state selects multiple model drugs within the same therapeutic class (for example, two competing SGLT2 inhibitors or two biologic immunology agents from different participating manufacturers), the state may not disfavor one participating manufacturer relative to the other on its Preferred Drug List. Both products must receive equal preferred tier placement, preventing the state from playing manufacturers against each other in annual supplemental rebate bidding wars.
How does GENEROUS interact with the statutory rebate, Medicaid Best Price, and 340B ceiling prices?
For pharmaceutical manufacturers evaluating whether to sign GENEROUS agreements, the single most critical structural feature is its statutory firewall from Medicaid Best Price and the 340B Drug Pricing Program.
┌─────────────────────────────────────────────────────────────────────────┐
│ Medicaid Best Price & 340B Firewall Comparison │
├──────────────────────────────────┬──────────────────────────────────────┤
│ Transaction Type │ Impact on Best Price & 340B Ceiling │
├──────────────────────────────────┼──────────────────────────────────────┤
│ Commercial Payer / PBM Rebates │ • Enters Best Price calculation; │
│ (Deep Commercial Discounts) │ • Can reset national 340B ceiling │
│ │ to statutory penny-pricing floor │
├──────────────────────────────────┼──────────────────────────────────────┤
│ Value-Based Contract Concessions │ • High risk of triggering Best Price │
│ (Without multiple BP reporting) │ penalties across entire Medicaid │
├──────────────────────────────────┼──────────────────────────────────────┤
│ CMS-Authorized GENEROUS SRA │ • EXEMPT from Medicaid Best Price │
│ (Section 1115A Supplemental) │ • ZERO impact on 340B ceiling price │
│ │ • Protects commercial revenue base │
└──────────────────────────────────┴──────────────────────────────────────┘
The Statutory Exemption
The operative text is regulatory, not statutory. 42 CFR 447.505(c)(7) excludes from best price "[r]ebates under the national rebate agreement or a CMS-authorized supplemental rebate agreement paid to State Medicaid Agencies under section 1927 of the Act." A supplemental rebate only earns this treatment because it is paid under a CMS-authorized SRA — which is precisely the vehicle GENEROUS uses.
The CMS State RFA states the consequence directly: "supplemental Medicaid rebates that are provided pursuant to a CMS-authorized supplemental rebate agreement do not affect best price or 340B ceiling prices."
- No Best Price Drag: The deep international MFN discounts provided to Medicaid states do not flow into the manufacturer's quarterly Best Price filings. A manufacturer can offer a 60% supplemental rebate to Medicaid without triggering a catastrophic price-concession cascade across its commercial, Medicare Part D, or commercial health plan contracts.
- Zero Impact on 340B Ceilings: Because statutory 340B ceiling prices are computed directly from Average Manufacturer Price (AMP) minus the basic Medicaid URA, and because CMS-authorized supplemental rebates do not alter AMP or basic URA, the GENEROUS model does not lower 340B ceiling prices for covered entities.
This stands in sharp contrast to the contracting dynamics we analyzed in Medicaid best-price risk in contracting and the ongoing litigation surrounding the 340B rebate-model ruling.
Which states gain most, and which already negotiate a better deal on their own?
Medicaid prescription drug spending represents one of the largest and fastest-growing line items in state budgets. CMS states on the GENEROUS model page that net Medicaid prescription drug spending topped $60 billion in 2024, an increase of $10 billion (20%) from 2022. Separately, MACPAC's MACStats Exhibit 28 puts FY 2024 gross Medicaid drug spending at $106.4 billion against $58.4 billion in rebates. Do not subtract one source from the other: CMS reports calendar-year net spending, MACPAC reports fiscal-year gross spending drawn from state drug utilization data with rebates drawn from the CMS-64, and MACPAC's own notes warn that rebates collected in a period are generally attributable to drugs purchased in earlier periods, so gross and rebate dollars for a given window are not aligned.
KFF's analysis of that MACPAC data finds Medicaid rebates reduced gross drug spending by 53% on average from FY 2019 to FY 2024, with state supplemental rebates contributing 7% of the gross reduction in FY 2024 alone. KFF also identifies four states where rebates offset less than 40% of gross spending (Kentucky, Oregon, South Dakota, Virginia) and four where they offset more than 90% (Delaware, Mississippi, Nevada, Wyoming).
That split is the standard evidence cited for "rebate capture varies enormously by state," and it is directionally right. But recomputing the shares directly from Exhibit 28 shows how much of the tail is data artifact rather than negotiating skill:
┌───────────────────────────────────────────────────────────────────────────┐
│ Medicaid Rebates as a Share of Gross Drug Spending, FY 2024 │
├────────────────┬────────────┬──────────────┬────────┬─────────────────────┤
│ State │ Gross ($M) │ Rebates ($M) │ Share │ MACPAC note │
├────────────────┼────────────┼──────────────┼────────┼─────────────────────┤
│ Oregon │ 895.5 │ +62.6 │ n/a │ prior-period adj. │
│ Virginia │ 6,194.8 │ -1,272.8 │ 20.5% │ generic-mix anomaly │
│ South Dakota │ 229.1 │ -61.9 │ 27.0% │ — │
│ Kentucky │ 4,282.4 │ -1,391.3 │ 32.5% │ Q3 spending anomaly │
│ . . . │ │ │ │ │
│ Nevada │ 542.9 │ -508.6 │ 93.7% │ — │
│ Delaware │ 260.9 │ -245.3 │ 94.0% │ — │
│ Mississippi │ 596.1 │ -652.0 │ 109.4% │ exceeds 100% │
│ Wyoming │ 34.7 │ -40.6 │ 117.0% │ exceeds 100% │
└────────────────┴────────────┴──────────────┴────────┴─────────────────────┘
Shares computed as rebates divided by gross spending from MACStats Exhibit 28 (FY 2024), national total $106,395.0M gross against $58,406.1M rebates, or 54.9%.
Three of the four low-rebate states carry an explicit MACPAC footnote. Oregon reported prior-period managed care adjustments that produced a positive managed care rebate amount, so no meaningful share can be computed for it at all. Virginia is footnoted for an atypical proportion of generic spending that "may indicate data anomalies." Kentucky is footnoted for anomalous Q3 FY 2024 spending. Only South Dakota's 27.0% is unflagged. At the other end, Mississippi and Wyoming exceed 100% — rebates larger than the same period's gross spending — which is a timing artifact of the collection lag, not evidence that those states buy drugs for free.
The decision implication: a state director should not use this exhibit to judge whether their own program is a "low-rebate" candidate that stands to gain from GENEROUS. The comparison that matters is drug-by-drug — the state's existing supplemental rebate on a specific NDC-9 against that drug's GNUP — and the state has that number internally. Nothing published at the state-aggregate level substitutes for it.
The JAMA / Urban Institute Independent Findings
An independent empirical analysis by Hwang, Clemans-Cope, and Kesselheim — of Brigham and Women's Hospital/Harvard Medical School and the Urban Institute — was published as a research letter in JAMA (JAMA. 2026;336(6):514-517; doi:10.1001/jama.2026.9973; PubMed ID 42455531), released online July 17, 2026. It modeled the fiscal impact of MFN pricing across 82 high-spending brand-name drugs, using CMS drug utilization data from July 2024 through June 2025, covering all 50 states and the District of Columbia.
┌────────────────────────────────────────────────────────────────────────┐
│ JAMA / Urban Institute Study: Model Findings (82 Drugs) │
├────────────────────────────────────────────────────────────────────────┤
│ • Estimated annual Medicaid savings: $8.6 billion, accruing across │
│ 47 states and DC (three states realize none) │
│ • Share of net spending on the studied drugs: ~35% │
│ • Share of studied drugs priced lower abroad than current US │
│ Medicaid net price: ~90% │
│ • 17 participating manufacturers account for 88% of Medicaid spending │
│ on these drugs and ~94% of the projected savings │
├────────────────────────────────────────────────────────────────────────┤
│ Largest percentage reductions — 59% to 66% of net drug spending, │
│ reported by the authors as a range for the group, not per state: │
│ Alaska · Hawaii · Massachusetts · Rhode Island │
├────────────────────────────────────────────────────────────────────────┤
│ No savings (existing supplemental rebates already exceed the model): │
│ Oklahoma · Mississippi · North Dakota │
└────────────────────────────────────────────────────────────────────────┘
The authors report 59% to 66% as a range across those four states and do not publish an individual figure for each one; any per-state number attributed to this study should be treated as unsourced.
The Counter-Estimate Nobody Puts Next to It
The $8.6 billion figure is the optimistic end of the published range, and a state director should see the other one. The White House Council of Economic Advisers estimated that a voluntary MFN framework in Medicaid would save $64.3 billion over ten years — roughly $6.43 billion a year, or about 14% of annual Medicaid prescription drug spending. The two estimates differ by about a third on the annual figure and by a factor of two-and-a-half on the percentage, because they price different things: the JAMA letter models 82 specific high-spend brands with full manufacturer participation, while the CEA figure spreads across the whole benefit. Neither is a forecast of what any individual state will collect, because what a state collects depends entirely on the supplemental rebate it already has on the specific drugs it selects.
Why Do Some States Gain While Others Lose?
- The Gaining States (AK, HI, MA, RI): The authors' stated mechanism is simple and worth not over-embellishing — these are states with minimal existing supplemental rebates on the studied drugs. Where a state is collecting little beyond the statutory URA today, dropping to an international benchmark moves the net price a long way.
- The Zero-Savings States (OK, MS, ND): These states already extract supplemental rebates that exceed what the model would deliver, so a GENEROUS agreement would mean adopting federally negotiated coverage criteria in exchange for less net rebate than they collect today. The MACPAC exhibit corroborates this from an independent direction: Mississippi (109.4%), North Dakota (87.9%), and Oklahoma (84.4%) all sit in the top decile of FY 2024 rebate capture. Two published datasets built on different inputs agreeing on the same three states is a stronger signal than either alone.
- Intersection with State PDABs: In states with active Prescription Drug Affordability Boards, which we monitor in our state affordability board launch risk tracker, regulators must evaluate whether a voluntary federal rebate model interacts with or preempts state-level Upper Payment Limits (UPLs).
What does a manufacturer access team have to rebuild before a state signs a supplemental rebate agreement?
To implement the GENEROUS model, pharmaceutical manufacturers, state Medicaid agencies, and managed care plans must execute a synchronized three-document contractual architecture:
┌─────────────────────────────────────────────────────────────────────────┐
│ GENEROUS Three-Document Contracting Architecture │
├─────────────────────────────────────────────────────────────────────────┤
│ │
│ ┌──────────────┐ CMS-Manufacturer Key Terms ┌──────────────┐ │
│ │ CMS │◄─────────────────────────────────►│ Manufacturer │ │
│ └──────┬───────┘ └──────┬───────┘ │
│ │ │ │
│ │ CMS-State Participation Agreement │ │
│ ▼ │ │
│ ┌──────────────┐ CMS-Authorized Model SRA │ │
│ │ State │◄─────────────────────────────────────────┘ │
│ │ Medicaid │ │
│ └──────┬───────┘ │
│ │ Managed Care Contract Template (MCO / PBM Addenda) │
│ ▼ │
│ ┌──────────────┐ │
│ │ MCOs / PBMs │ (Uniform Coverage Criteria & SRA Pass-Through) │
│ └──────────────┘ │
└─────────────────────────────────────────────────────────────────────────┘
Operational Workflows for Access and Contracting Leads
- Document 1: CMS-Manufacturer Agreement on Key Terms: Formalizes the participating manufacturer's model drug portfolio, audits international net prices, and fixes the GNUP benchmarks for the initial 12-month performance period.
- Document 2: CMS-State Participation Agreement: Establishes the state's legal commitment to adopt federal uniform coverage criteria and adhere to the same-class non-discrimination rules.
- Document 3: State-Manufacturer Supplemental Rebate Agreement (SRA): The bilateral executing contract authorized by CMS that governs quarterly invoicing, dispute resolution, and payment flows.
- Managed Care Contract Addenda: For states that contract with managed care plans providing a pharmacy benefit, CMS supplies a contract template for those plans — MCOs, prepaid inpatient health plans, and prepaid ambulatory health plans — and their PBMs, covering use of the model's coverage criteria. States that participate may further tailor these addenda. Note that managed care enrollment and pharmacy carve-in are different questions: several large states (California, New York, Tennessee, West Virginia, Missouri) run heavy managed care enrollment while carving the pharmacy benefit back out to fee-for-service, so a state's MCO penetration figure does not tell you how much of this contracting work it faces.
- Invoicing and Payment Clocks: States must submit quarterly supplemental rebate invoices to manufacturers within 60 days of quarter end. Manufacturers must remit payment within 37 calendar days of receipt, after which statutory interest penalties begin accruing.
For therapies in high-cost classes, such as GLP-1 receptor agonists, states must also consider class-specific policy nuances, as detailed in our tracker on Medicaid GLP-1 coverage state by state.
Decision Matrix: How a State Medicaid Director Should Decide by September 10
State Medicaid pharmacy directors evaluating participation must avoid an all-or-nothing mindset. Because the model allows selective drug-by-drug enrollment, state teams should apply a disciplined four-step evaluation algorithm:
┌────────────────────────────────────────────────────────────────────────┐
│ State Medicaid Director Evaluation Algorithm │
├────────────────────────────────────────────────────────────────────────┤
│ Step 1: Net Price Comparison (Drug-by-Drug) │
│ └── Calculate: Current State Net Price vs. Model GNUP │
│ ├── If Model GNUP < Current Net Price ──► PROCEED TO STEP 2 │
│ └── If Current Net Price ≤ Model GNUP ──► EXCLUDE DRUG FROM MODEL │
├────────────────────────────────────────────────────────────────────────┤
│ Step 2: Clinical Utilization Management Assessment │
│ └── Compare: State PDL Criteria vs. CMS Uniform Coverage Criteria │
│ ├── If Federal Criteria align with state clinical guidelines ──► │
│ │ SELECT DRUG FOR GENEROUS PARTICIPATION │
│ └── If Federal Criteria expand utilization beyond budget tolerance │
│ └── Model volume surge vs. unit price savings │
├────────────────────────────────────────────────────────────────────────┤
│ Step 3: Class-Level Non-Discrimination Audit │
│ └── Identify all model drugs in target therapeutic class │
│ └── Verify state is willing to co-prefer all participating brands │
├────────────────────────────────────────────────────────────────────────┤
│ Step 4: Execute State Application by September 10, 2026 │
└────────────────────────────────────────────────────────────────────────┘
Frequently Asked Questions (FAQ)
Is the GENEROUS model mandatory for states or pharmaceutical manufacturers?
No. The GENEROUS model is entirely voluntary for both manufacturers and state Medicaid agencies under Section 1115A demonstration authority. Neither states nor manufacturers face financial penalties for declining to participate.
Does a GENEROUS supplemental rebate lower Medicaid Best Price or 340B ceiling prices?
No. Supplemental rebates paid under a CMS-authorized Supplemental Rebate Agreement are statutorily excluded from the calculation of Medicaid Best Price under Section 1927 of the Social Security Act. Consequently, they do not reduce Average Manufacturer Price (AMP) or basic Unit Rebate Amounts (URA), leaving 340B statutory ceiling prices completely unchanged.
Can a participating state still negotiate its own supplemental rebates on model drugs?
No. A state that elects to receive GENEROUS pricing on a specific covered outpatient drug is prohibited from negotiating additional state-specific supplemental rebates on that drug. However, the state retains full legal authority to negotiate independent supplemental rebates on all non-model drugs and across non-participating manufacturers.
Which eight countries set the Most-Favored-Nation benchmark?
The eight reference nations established in the CMS Request for Applications are the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland. The benchmark price is the second-lowest manufacturer-reported net price among these eight countries, adjusted for GDP per capita on a Purchasing Power Parity (PPP) basis.
Does the GENEROUS model lower out-of-pocket prescription drug costs for Medicaid enrollees?
Not materially. Medicaid cost sharing is capped by federal rule at 42 CFR 447.52–447.56: amounts are nominal for enrollees at or below 100% FPL and are indexed annually to the medical care component of CPI-U, states may impose higher charges for non-preferred drugs only within defined income tiers, and many groups and services are exempt from cost sharing entirely. Because enrollee cost sharing is set by those rules rather than by what the state pays for the drug, GENEROUS savings accrue to state and federal Medicaid budgets — shared through the state's FMAP, as under the standard rebate program — rather than reducing point-of-sale out-of-pocket costs.
How does the model apply to Medicaid Managed Care Organizations (MCOs) and their PBMs?
CMS provides standardized contract templates and addenda that participating states must incorporate into their managed care contracts. MCOs and their PBMs are contractually required to apply the federally negotiated uniform coverage criteria and pass through all utilization data required for state quarterly supplemental rebate invoicing.
Sources
- Centers for Medicare & Medicaid Services (CMS), Innovation Center. GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model Overview and FAQs. Content updated July 2026. CMS Innovation Center.
- Centers for Medicare & Medicaid Services (CMS). GENEROUS Model State Request for Applications (RFA). Official Model Guidance. State RFA released December 2025 (the manufacturer RFA was released November 6, 2025); guidance active 2026. CMS Priorities.
- Centers for Medicare & Medicaid Services (CMS). GENEROUS Model Request for Applications for Drug Manufacturers. Official Solicitation. CMS Innovation Models.
- Centers for Medicare & Medicaid Services (CMS). CMS Extends Deadlines for GENEROUS Model Applications for Drug Manufacturers and States. News Alert. Published April 29, 2026. CMS Newsroom.
- Centers for Medicare & Medicaid Services (CMS). State Letter of Intent (LOI) for Medicaid GENEROUS Model. CMMI Demonstration Application. CMS LOI Portal.
- KFF (Kaiser Family Foundation). A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs. Issue Brief. Published 2026. KFF Medicaid.
- JAMA / Urban Institute. Hwang TJ, Clemans-Cope L, Kesselheim AS. Savings Under Most-Favored-Nation Pricing for Prescription Drugs in Medicaid. Research Letter. JAMA. 2026;336(6):514-517. doi:10.1001/jama.2026.9973; released online July 17, 2026; PubMed ID 42455531. PubMed.
- Medicaid and CHIP Payment and Access Commission (MACPAC). Medicaid Gross Spending and Rebates for Drugs by Delivery System, FY 2024 (Exhibit 28). MACStats Data Table. Published January 2026. MACPAC.
- White House Council of Economic Advisers (CEA). Savings from Most-Favored-Nation Drug Pricing Policy. Economic Analysis. Published May 2026. White House CEA.
- Georgetown University Center for Children and Families (CCF). Several Key Questions about Administration Drug Pricing Deals and Their Impact on Medicaid. Policy Brief. Georgetown CCF.
- Mercer Government Human Services Consulting. FLASH: GENEROUS Drug Rebate Model Implementation Considerations. Technical Alert. Mercer Government.
- U.S. Social Security Administration / Centers for Medicare & Medicaid Services. Section 1927 of the Social Security Act: Payment for Covered Outpatient Drugs (42 U.S.C. § 1396r-8). Statutory Compilation. SSA Compilation.
- Electronic Code of Federal Regulations. 42 CFR 447.505 — Determination of best price, and 42 CFR 447.52–447.56 — Medicaid premiums and cost sharing. eCFR.
